Abstract 385P
Background
STK11 mutations are found in approximately 15–35% of non-small cell lung cancer (NSCLC) patients and often co-occur with KRAS mutations. However, the subgroup of STK11-mutated patients presenting without KRASas a co-mutation has been poorly characterized, both molecularly and clinically.We analyzed this subgroup in more detail and compared it with the subgroup without KRAS mutations.
Methods
We collected molecular data from NSCLC patients diagnosed and tested by next-generation sequencing (NGS) between the years 2022 and now within the Network Genomic Medicine (NGM) database. We analyzed both clinical characteristics and molecular findings.
Results
Of the 809 patients with STK11 mutation, 455 (56.2%) showed a co-occuring KRAS mutation and 354 (43.8%) had no detectable KRAS mutation. Most patients had adenocarcinoma histology (731/809, 90.4%), less frequent in the KRAS-negative (302/354, 85.3%) than in the KRAS-positive group (429/455, 94.3%). The median age at first diagnosis for the entire cohort was 65 years (range: 35–90 years), with no significant difference between the cohorts. The number of female patients was proportionally lower in the KRAS mutant group than in the non-mutant group (+KRAS: 249/455, 54.7%; −KRAS: 216/354, 61.0%. Fisher’s Exact: p=0.1). The proportion of never-smokers in the group with KRAS mutation (11/455, 2.4%) was less than half as high as in the group without KRAS mutation (19/354, 5.4%; p=0.04). In the UICC tumor stage recorded, the two groups differed as follows: +KRAS presenting with stage: I: 20 (4.4%), II: 12 (2.6%), III: 55 (12.1%), IV: 264 (58.0%); –KRAS presenting with stage I: 15 (4.2%), II: 5 (1.4%), III: 45 (12.7%), IV: 198 (55.9%).
Conclusions
Our analysis revealed remarkable and partly significant differences in the clinical presentation of STK11-mutant NSCLC with or without co-occurring KRAS mutations. Further work focusing on the molecular and prognostic differences is ongoing.
Legal entity responsible for the study
University Hospital of Cologne
Funding
Has not received any funding
Disclosure
All authors have declared no conflicts of interest.